企業プロフィール
Supernus 株価・ニュース・カタリスト
- ティッカー:
- SUPN
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
45.85 USD (-3.37%)
終値
最終更新: 2026年8月21日
2.56B USD
時価総額
株価変動の要因
As of Aug 21, 2026, SUPN closed down 3.37% at $45.85. No new same-company headline was identified in the current news window.
企業概要
CNS Commercial Portfolio
Supernus Pharmaceuticals develops and commercializes treatments for central nervous system disorders. Its marketed portfolio spans attention-deficit hyperactivity disorder, Parkinson’s disease, postpartum depression, epilepsy, migraine, cervical dystonia and chronic sialorrhea.
Growth Products
The company’s principal growth brands include Qelbree for ADHD, GOCOVRI for dyskinesia in Parkinson’s disease, ONAPGO for continuous treatment of motor fluctuations in Parkinson’s disease and ZURZUVAE for postpartum depression. ZURZUVAE is commercialized through an economic collaboration with Biogen.
Epilepsy and Depression Pipeline
SPN-817 is a selective acetylcholinesterase inhibitor in a Phase 2b trial for treatment-resistant focal seizures. SPN-820 is designed to increase mTORC1-mediated synaptic function and is in Phase 2b development as an adjunctive treatment for major depressive disorder.
ADHD Pipeline Expansion
SPN-443 is a novel stimulant candidate for ADHD. Its planned first-in-human study extends Supernus’s pipeline within a therapeutic area where the company already has commercial infrastructure through Qelbree.
今後のカタリスト
- Phase 1 initiation for SPN-443 expected in the second half of 2026.
- FDA submission for a second ONAPGO supplier expected in the third quarter of 2026, with potential approval by mid-2027.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。